Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTCR-P1 in advanced solid tumors
NCT03970382Phase 1Suspended
- Sponsor
- PACT Pharma
- Start
- Jul 2019
- Primary completion
- Aug 2022
- Modality
- Adoptive Cell Transfer, Gene Silencing, CRISPR-Cas9
- Countries
- 1
01
Overview
Phase 1, open-label trial of NeoTCR-P1 in solid tumor, melanoma, urothelial carcinoma (UC) and 4 more (3 arms), sponsored by PACT Pharma. Primary endpoints: Incidence of adverse events as defined as DLTs at 28 days, Number of participants with adverse events at 2 years and 2 more. Started Jul 2019; status: suspended.
02
Drugs
NeoTCR-P1
03
Conditions
solid tumormelanomaurothelial carcinoma (UC)ovarian cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03970382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970382.